GO
Loading...

Merck & Co Inc

More

  • Jan 20- Johnson& Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck& Co.. He predicted the stronger dollar will take a bigger bite out of other drugmakers' earnings than many...

  • J&J Ebola vaccine gets $115M to speed development Friday, 16 Jan 2015 | 8:57 AM ET
    A worker in vaccine production at drugmaker GlaxoSmithKline in Saint-Amand-les-Eaux, France.

    Johnson & Johnson said that newly formed groups supporting work on its experimental Ebola vaccine would receive $115 million to speed development.

  • SAN FRANCISCO/ WASHINGTON Jan 15- U.S. healthcare executives say Obamacare is likely here to stay, despite repeated calls from Republican lawmakers for repeal of the 2010 law aimed at providing health coverage for millions of uninsured Americans. Top executives who gathered in San Francisco this week for the annual J.P. Morgan Healthcare conference, say that...

  • Healthcare Executives on a Saturday  Thursday, 15 Jan 2015 | 10:30 AM ET

    Healthcare executives talk about their weekend activities.

  • 9 stocks that'll get you through the storm Thursday, 15 Jan 2015 | 10:17 AM ET

    These nine stocks are faring well despite the tumultuous market, USA Today reports.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • HALFTIME FINAL TRADES 1/14/15 Wednesday, 14 Jan 2015 | 2:31 PM ET
  • Midday movers: Aetna, Ocwen Financial, GoPro & more Tuesday, 13 Jan 2015 | 1:13 PM ET

    Some of Tuesday's midday movers:

  • SAN FRANCISCO, Jan 12- Eli Lilly and Co said on Monday that U.S. insurers are increasing pressure on the price of diabetes medications as they switch coverage from certain drugs to others to trim costs. "We've definitely seen increased price competition, more by payers than the companies themselves," Lilly Chief Financial Officer Derica Rice said on Monday in an...

  • 11 ways to play biotech Monday, 12 Jan 2015 | 6:59 PM ET

    Traders on CNBC's "Fast Money" outlined their strongest plays in the ever-volatile biotechnology space.

  • Merck CEO: Deals create value  Monday, 12 Jan 2015 | 4:27 PM ET

    Merck CEO Ken Frazier plans to focus on its specialized area strategy in 2015, with CNCB's Meg Tirrell.

  • TRENTON, N.J.— Drugmaker Merck& Co. is ratcheting up its race with rival Bristol-Myers Squibb Co. for leadership in one of today's hottest research areas, immuno-oncology, which harnesses the immune system to fight cancer. Merck CEO Kenneth Frazier was to announce that Merck, based in Kenilworth, New Jersey, has more than 10 drugs in late-stage patient testing and...

  • ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis business Foundation Medicine, it said on Monday, signalling its determination to expand in cancer immunotherapy by paying a hefty mark-up on the U.S. company's current price. The deal will help the world's largest maker of cancer drugs push ahead in...

  • Jan 9- An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. Sanofi SA and Regeneron are in a fierce race with Pfizer and Amgen Inc to bring their PCSK9 inhibitor to the market, which is expected to be worth billions if these...

  • Cramer Remix: Party with these rock star stocks Thursday, 8 Jan 2015 | 7:15 PM ET
    Jim Cramer on Mad Money.

    "Mad Money" host Jim Cramer on the players that could keep tearing it up in 2015.

  • S&P 500 records longest loss streak since late 2013 Tuesday, 6 Jan 2015 | 4:37 PM ET
    Traders work on the floor of the New York Stock Exchange, Oct. 29, 2014.

    Stocks fell Tuesday as investors fretted the implications of crude's failure to find a floor.

  • J&J and Bavarian Nordic start Ebola vaccine tests Tuesday, 6 Jan 2015 | 5:03 AM ET
    Amanda Smith, graduate student from the University of Utah, holds a container with test material in a sealed lab with a non-infective forum of the Ebola virus to help discover a drug that is effective against a part of Ebola that is vulnerable to drugs, on October 14, 2014 in Salt Lake City, Utah.

    Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic.

  • Jan 5- Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Shares of Cempra, among a clutch of smaller companies developing treatments to fight super-bugs, rose as much as 18 percent to $27.10 in early trading on Monday. WBB Securities' Steve...

  • Early Movers: CAT, INTC, PBPB, BSX, CEMP & more Monday, 5 Jan 2015 | 8:52 AM ET

    Companies making headlines ahead the bell Monday:

  • Jan 5- Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Data showed solithromycin actually outperformed moxifloxacin by a slight margin, Cempra said on Sunday. North Carolina- based Cempra is also evaluating an intravenous formulation of...